<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04606615</url>
  </required_header>
  <id_info>
    <org_study_id>ADRN3-CRC</org_study_id>
    <nct_id>NCT04606615</nct_id>
  </id_info>
  <brief_title>Skin Barrier Abnormalities and Oxidative Stress Response</brief_title>
  <official_title>Skin Barrier Abnormalities and Oxidative Stress Response in the Skin of Atopic Dermatitis Patients With Food Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-site controlled observational study designed to comprehensively&#xD;
      determine whether children and adults with atopic dermatitis (AD) and food allergy (FA) have&#xD;
      skin abnormalities which distinguish them from children with AD without FA, and non-atopic&#xD;
      (NA) controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Transepidermal Water Loss (TEWL)</measure>
    <time_frame>Day 0</time_frame>
    <description>area under the TEWL curve (AUC) from four non-lesional skin sites assessed. TEWL will be assessed on non-lesional skin prior to tape stripping and repeated after 5, 10, 15, and 20 tape strips.</description>
  </primary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Food Allergy</condition>
  <arm_group>
    <arm_group_label>Adults: AD + FA</arm_group_label>
    <description>Adults: atopic dermatitis and food allergy to peanut</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults: AD - FA</arm_group_label>
    <description>Adults: atopic dermatitis and no food allergy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults: NC</arm_group_label>
    <description>Adults: Normal Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children: AD+ Peanut</arm_group_label>
    <description>Children: atopic dermatitis and food allergy to peanut</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children: AD + Milk</arm_group_label>
    <description>atopic dermatitis and food allergy to milk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children: AD + Egg</arm_group_label>
    <description>atopic dermatitis and food allergy to egg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children: AD only</arm_group_label>
    <description>atopic dermatitis and no food allergy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children: NC</arm_group_label>
    <description>Normal Control</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will children and adults. We will include children aged 1-17 years. We&#xD;
        will enroll up to 20 AD children with food allergy to peanut, up to 20 AD children with&#xD;
        food allergy to milk and no peanut allergy, up to 20 AD children with food allergy to eggs&#xD;
        and no peanut allergy, up to 20 AD children without a history of food allergy, and up to 20&#xD;
        NA children. In addition, 18-65 old adults will be enrolled, including up to 20 adults with&#xD;
        food allergy to peanut, up to 20 adults with AD without history of food allergy and 20&#xD;
        healthy controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, 1 to 17 years of age inclusive at Screening for the pediatric group,&#xD;
             18-65 years of age for the adult group&#xD;
&#xD;
          2. For all pediatric participants parent guardian must be able to understand and provide&#xD;
             informed consent and participant provide assent as applicable per Institutional Review&#xD;
             Board (IRB) guidelines and regulations&#xD;
&#xD;
          3. Children: active AD and food allergy to peanut OR active AD and food allergy to milk&#xD;
             OR active AD and food allergy to eggs. Adults: active AD and food allergy to peanut.&#xD;
             Participant must meet all of the following criteria:&#xD;
&#xD;
               -  Self-report or documentation of a positive oral food challenge to peanut OR egg&#xD;
                  OR milk or self-report of an allergic reaction to peanut OR egg OR milk within 2&#xD;
                  hours of ingestion&#xD;
&#xD;
               -  Skin prick test whealâ‰¥8mm for peanut, milk or egg OR&#xD;
&#xD;
               -  Active AD and no food allergy. Participant must meet all of the following&#xD;
                  criteria:&#xD;
&#xD;
               -  No personal history or current manifestations of food allergy (based on no&#xD;
                  self-report of a positive oral food challenge, positive skin test, positive blood&#xD;
                  test, or allergic reactions)&#xD;
&#xD;
               -  Negative skin prick test (wheal&lt;3mm) to peanut, milk, egg, wheat, soy, shellfish&#xD;
                  mix, treenuts, and sesame seed OR&#xD;
&#xD;
        NA. Participant must meet all of the following criteria:&#xD;
&#xD;
          -  No personal history or current manifestations of AD, asthma, or allergic rhinitis&#xD;
             (based on self-report)&#xD;
&#xD;
          -  No personal history or current manifestations of food allergy (based on no self-report&#xD;
             of a positive oral food challenge, positive skin test, positive blood test, or&#xD;
             allergic reactions)&#xD;
&#xD;
          -  Negative skin pricktest (wheal&lt;3mm) to peanut, milk, egg, wheat, soy, shellfish mix,&#xD;
             treenuts, and sesame seed&#xD;
&#xD;
          -  Negative skin prick test(wheal&lt;3mm) to environmental allergens (cat, dog, dustmite,&#xD;
             cockroach, and local trees/grasses/weeds/molds)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Inability or unwillingness of a parent guardian (for pediatric participants) to&#xD;
             give written informed consent, or participant to give assent, if applicable, or to&#xD;
             comply with study protocol 2. Who have any skin disease other than AD that might&#xD;
             compromise the stratum corneum barrier (e.g., bullous diseases, psoriasis, cutaneous T&#xD;
             cell lymphoma [also called Mycosis Fungoides or Sezary syndrome], dermatitis&#xD;
             herpetiformis, Hailey-Hailey, or Darier's disease).&#xD;
&#xD;
             3. Pregnant or lactating females 4. Known or suspected immunosuppression 5. Severe&#xD;
             concomitant illness(es) 6. History of serious life-threatening reaction to latex,&#xD;
             tape, or adhesives 7. Past or current medical problems or findings from physical&#xD;
             examination or laboratory testing that are not listed above, which, in the opinion of&#xD;
             the investigator, may pose additional risks from participation in the study, may&#xD;
             interfere with the participant's ability to comply with study requirements or that may&#xD;
             impact the quality or interpretation of the data obtained from the study 8. Use of&#xD;
             biologics within 5 half-lives (if known) or 16 weeks of the Screening Visit 9. Use of&#xD;
             an investigational drug within 5 half-lives (if known) or 8 weeks of the Screening&#xD;
             Visit 10. Has received immunotherapy within 12 months of the Screening Visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elena Goleva, PhD</last_name>
    <phone>303.398.1637</phone>
    <email>golevae@njhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Sussman</last_name>
      <phone>303-398-1717</phone>
      <email>sussmanj@njhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Elena Goleva</last_name>
      <email>golevae@njhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Elena Goleva, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

